21 Result(s)
within
Article
David Schrama
Cancer Research
-
Article
Open AccessInhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion
The mitogen-activated protein kinase (MAPK) signaling pathway is frequently hyperactivated in malignant melanoma and its inhibition has proved to be an efficient treatment option for cases harboring BRAFV600 muta...
-
Article
Open AccessIFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
Immune checkpoint inhibition and in particular anti-PD-1 immunotherapy have revolutionized the treatment of advanced melanoma. In this regard, higher tumoral PD-L1 protein (gene name: CD274) expression is associa...
-
Article
Open AccessElucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells
Targeting epigenetic modifiers is effective in cutaneous T cell lymphoma (CTCL). However, there is a need for further improvement of this therapeutic approach. Here, we compared the mode of action of romidepsi...
-
Article
Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC
Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or...
-
Article
MGMT promoter methylation status in Merkel cell carcinoma: in vitro versus invivo
Expression of O6-methylguanine-DNA methyltransferase (MGMT) in Merkel cell carcinoma (MCC) is very variable; thus, we tested whether this may be due to differential methylation of the MGMT gene promoter.
-
Article
Non-reproducible sequence artifacts in FFPE tissue: an experience report
Recent advances in sequencing technologies supported the development of molecularly targeted therapy in cancer patients. Thus, genomic analyses are becoming a routine part in clinical practice and accurate det...
-
Article
Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients
TERT promoter mutations were detected at high frequencies in several cancer types including melanoma. Previous reports showed that these recurrent mutations increase TERT gene expressi...
-
Article
Immune-suppressive properties of the tumor microenvironment
Solid tumors are more than an accumulation of cancer cells. Indeed, cancerous cells create a permissive microenvironment by exploiting non-transformed host cells. Thus, solid tumors rather resemble abnormal or...
-
Article
Open AccessCellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma
Grm1-transgenic mice spontaneously develop cutaneous melanoma. This model allowed us to scrutinize the generic immune responses over the course of melanoma development. To this end, lymphocytes obtained from s...
-
Article
Open AccessSurvivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma
Therapeutic vaccination directed to induce an anti-tumoral T-cell response is a field of extensive investigation in the treatment of melanoma. However, many vaccination trials in melanoma failed to demonstrate...
-
Article
Open AccessImmunogenicity of HLA-A1-restricted peptides derived from S100A4 (metastasin 1) in melanoma patients
S100A4 (metastasin 1) belongs to the S100 family of Ca2+ binding proteins. While not present in most differentiated adult tissues, S100A4 is upregulated in the micromilieu of tumors. It is primarily expressed by ...
-
Article
Open AccessCancer treatment: the combination of vaccination with other therapies
Harnessing of the immune system by the development of ‘therapeutic’ vaccines, for the battle against cancer has been the focus of tremendous research efforts over the past two decades. As an illustration of th...
-
Article
Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy
Chemokines influence both tumor progression and anti-tumor immune response. A 32-bp-deletion polymorphism in the chemokine receptor 5 gene (CCR5Δ32) has been shown to result in a non-functional protein. This s...
-
Article
Immunological tumor destruction in a murine melanoma model by targeted LTα independent of secondary lymphoid tissue
We previously demonstrated that targeting lymphotoxin α (LTα) to the tumor evokes its immunological destruction in a syngeneic B16 melanoma model. Since treatment was associated with the induction of peritumor...
-
Article
Anti-cancer therapies targeting the tumor stroma
For anti-tumor therapy different strategies have been employed, e.g., radiotherapy, chemotherapy, or immunotherapy. Notably, these approaches do not only address the tumor cells themselves, but also the tumor ...
-
Article
Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression
Recent reports have demonstrated that the enzyme indoleamine 2,3-dioxygenase (IDO) is upregulated in human dendritic cells (DCs) upon in vitro maturation. IDO is supposed to convey immunosuppressive effects by...
-
Article
Therapeutic efficacy of tumor-targeted IL2 in LTα−/− mice depends on conditioned T cells
An effective immunological eradication of tumors by the adaptive immune system depends on T cell priming, expansion of specific T cells and their effector function. It has been shown that either step may be im...
-
Article
Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes
It is generally believed that priming of efficient T-cell responses takes place in peripheral lymphoid tissues. Although this notion has been rigidly proven for infectious diseases, direct evidence for lymph n...
-
Article
Tumor stroma-associated antigens for anti-cancer immunotherapy
Immunotherapy has been widely investigated for its potential use in cancer therapy and it becomes more and more apparent that the selection of target antigens is essential for its efficacy. Indeed, limited cli...
-
Article
Antibody targeted drugs as cancer therapeutics
One way to maximize the effect and minimize the side effects of cancer therapeutics is the targeting of drugs to the tumor by using the specificity of antibodi...
